Female medical practitioner reassuring a patient

ljubaphoto

Electromed, Inc. (NYSE:ELMD) recently reported an impressive quarter, and noted beneficial expectations for the year 2024. With a total market opportunity of close to 4.2 million patients suffering from Bronchiectasis, I assumed that the total market opportunity could be around $8.4

Source link